Methods and compositions for reducing toxicity associated with leflunomide treatment

• US 20060024376A1
• Filed: 07/30/2004
• Published: 02/02/2006
• Est. Priority Date: 07/30/2004
• Status: Abandoned Application

• Current Assignee: University of Chicago The (University of Chicago)
• Original Assignee: University of Chicago
• Inventors: Williams, James W.
• Application Number:
  US10/903,681
• Publication Number:
  US 20060024376A1
• Time in Patent Office: Days
• US Class Current: 424/489
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/42 Oxazoles
• CPC Class Codes: A61K 31/505 Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• CPC Class Codes: A61K 31/513 having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• CPC Class Codes: A61K 9/0031 Rectum, anus
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention relates to methods and compositions useful in alleviating or reducing toxicity associated with leflunomide administration without reducing its bioactivity, e.g., without reducing its immunosuppressive activity, that is, utilizing a bioavailable pyrimidine compound to ameloriate the toxic effects caused by leflunomide compounds.

Claims

1. A pharmaceutical composition in unit dosage form for oral administration comprising an effective amount of a leflunomide compound;

and an orally bioavailable pyrimidine compound, salts thereof or a combination thereof;

together in a pharmaceutically acceptable carrier.

2. The composition of claim 1 wherein the pyrimidine compound is orotic acid, a salt thereof, triacetyluridine, a salt thereof, cytidine, a salt thereof, an acylated cytidine, a salt thereof, or a combination thereof.

3. The composition of claim 1, wherein the unit dosage contains 500 mg to 2000 mg of pyrimidine compound.

4. The composition of claim 1, wherein the leflunomide compound is leflunomide, A771726 or FK778.

5. The composition of claim 1, wherein the composition is formulated for controlled release.

6. The composition of claim 1, wherein the composition is formulated for rectal administration.

7. A pharmaceutical composition comprising a formulation for oral administration, the formulation comprising a therapeutically effective amount of leflunomide, and orotic acid or a salt thereof, and a pharmaceutically acceptable carrier.

8. A method of reducing toxicity associated with administration of a leflunomide compound to a patient in need thereof, comprising administering to the patient a toxicity-reducing amount of a bioavailable pyrimidine compound.

9. The method of claim 8, wherein the pyrimidine compound is orotic acid, a salt thereof, triacetyaluridine, a salt thereof, cytidine, a salt thereof, an acylated cytidine, a salt thereof, or a combination thereof.

10. The method of claim 8, wherein the pyrimidine compound is administered orally.

11. The method of claim 8, wherein the pyrimidine compound is administered in a daily dosage of from about 500 mg to about 2000 mg.

12. The method of claim 8, wherein the pyrimidine compound is co-administered substantially simultaneously with the leflunomide compound.

13. The method of claim 8, wherein the patient is a recipient of a transplant.

14. The method of claim 13, wherein the transplant is an allograft or a xenograft.

15. The method of claim 13, wherein the transplant is a heart, a kidney or bone marrow.

16. The method of claim 8, wherein the leflunomide compound is selected from a compound having

a) formula (II):

wherein R₁ and R₂ are independently selected from the group consisting of —

CF₃, —

H, —

Cl, —

F, —

Br, —

CN, —

COOH, —

OCH₃, —

NH—

CO—

CH₂Cl and —

NH—

CO—

CH₂Br;

or formula (IV);

wherein R₁ and R₂ are independently selected from the group consisting of —

CF₃, —

H, —

Cl, —

F, —

Br, —

CN, —

COOH, —

OCH₃, —

NH—

CO—

CH₂Cl and —

NH—

CO—

CH₂Br, and R3 is selected from the group consisting of C_1-5 alkyl, C_2-5 alkenyl, C_2-5 alkynyl, and C_3-6 cycloalkyl.

17. A method of extending the dosage range of a leflunomide compound comprising co-administering to a subject:

a) an effective amount of a leflunomide compound of formula (II);

wherein R₁ and R₂ are independently selected from the group consisting of —

CF₃, —

H, —

Cl, —

F, —

Br, —

CN, —

COOH, —

OCH₃, —

NH—

CO—

CH₂Cl and —

NH—

CO—

CH₂Br;

or formula (IV);

wherein R₁ and R₂ are independently selected from the group consisting of —

CF₃, —

H, —

Cl, —

F, —

Br, —

CN, —

COOH, —

OCH₃, —

NH—

CO—

CH₂Cl and —

NH—

CO—

CH₂Br; and

R₃ is selected from the group consisting of C_1-5 alkyl, C_2-5 alkenyl, C_2-5 alkynyl, and C_3-6 cycloalkyl; and

b) a toxicity-reducing amount of an orally bioavailable pyrimidine compound selected from the group consisting of orotic acid, a salt thereof, triacetyl uridine, a salt thereo, cytidine, a salt thereof, an acylated cytidine, a salt thereof, and a combination thereof.

18. A method of administering a toxic dose of a leflunomide compound to a mammal, comprising administering to the mammal an amount of an orally bioavailable pyrimidine compound sufficient to reduce the toxic effects of the leflunomide compound.

19. A method of reducing toxicity associated with the administration of a therapeutically effective amount of a leflunomide compound to a mammal, comprising:

orally administering to the mammal a bioavailable pyrimidine compound selected from orotic acid, a salt thereof, triacetyluridine, a salt thereof, cytidine, a salt thereof, an acylated cytidine, a salt thereof, and a combination thereof, in an amount effective to reduce the toxicity without blocking therapeutic

effect of the leflunomide compound, wherein the leflunomide compound is a compound of formula (II) or formula (IV).

20. The method of claim 19 wherein the pyrimidine compound is orotic acid or a salt thereof.

21. A method of treating rejection in a transplant recipient comprising co-administering

a therapeutically effective amount of a leflunomide compound and a toxicity-reducing effective amount of bio-available pyrimidine compound.

22. The method of claim 21, wherein the pyrimidine compound is orally bio-available.

23. The method of claim 22, wherein the pyrimidine compound is orotic acid, a salt thereof, triacetyl uridine, a salt thereof, cytidine, a salt thereof, an acylated cytidine, a salt thereof, or a combination thereof.

24. A method of achieving an effect in a patient comprising co-administering an effective amount of a leflunomide compound and an effective amount of orotic acid, a salt thereof, triacetyl uridine, a salt thereof, or a combination thereof, wherein the effect is treatment of rejection of a transplant, wherein the transplant is heart, kidney or bone marrow.

25. A pharmaceutical combination comprising a packaging having a plurality containers, at least one container containing a leflunomide compound, at least one other container containing a bioavailable pyrimidine compound, and an instructions for co-administering the leflunomide compound and the pyrimidine compound to a subject who is a transplant recipient.